The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|April 30, 2020
INTERPHEX Launches Online Resource for Pharma, Bio, and Device Content
Author(s)Pharmaceutical Technology Editors
The platform provides access to case studies, new technologies, expert insight, published and peer-reviewed articles, webinars, news updates, videos, and interviews.
Advertisement
INTERPHEX announced on April 23, 2020 that it is launching RECONNEX 365, a year-round online resource for pharma, bio, and device development and manufacturing content and information.
The platform provides access to case studies, new technologies, expert insight, published and peer-reviewed articles, webinars, news updates, videos, and interviews, according to a company press release. Exhibitors at INTERPHEX on April 20–22, 2021 at the Javits Center in New York, NY will have the ability to digitally introduce new and existing technical content, technologies, and solutions, while attendees will be able to schedule onsite meetings to experience the products, technologies, and services.
"Our new online resource reimagines procurement strategies and enables one to stay connected to the industry and leading suppliers year-round, setting companies with procurement needs up for future success," said Kate Scott, event director, INTERPHEX, in the press release. "Leading suppliers continue to select INTERPHEX to feature their innovative technologies, products, and services designed to reduce cost, increase productivity, and maximize efficiency."
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement